Despite recent advances in novel therapies for AML, there are numerous disease subtypes with extremely poor prognoses and no clear standards of care or recommended therapies. For these patients, evolving therapies represent the future and best hope, although the heterogeneity of the disease complicates many clinical trials and results are often mixed. In this accredited activity, a panel of national and international experts discuss the most exciting and innovative clinical trials today. Participants in this activity will gain key insights into questions such as, “Which triplet regimens should I be considering in my FLT-3 AML patients?”; “Why have recent clinical trials in anti-CD47 agents been terminated and is there still potential for therapies that target CD47 in AML?”; “What is the real future of bispecific antibodies and CAR T-cell therapies in AML?”; and “How can I, as a community oncologist, effectively treat my AML patients?”